Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma

STAR Protoc. 2020 Dec 2;1(3):100174. doi: 10.1016/j.xpro.2020.100174. eCollection 2020 Dec 18.

Abstract

Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).

Keywords: Cancer; Immunology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anatomic Landmarks
  • Animals
  • Cell Proliferation
  • Glioblastoma / immunology*
  • HEK293 Cells
  • Humans
  • Lentivirus / physiology
  • Lymphocyte Activation / immunology
  • Mice
  • Neoplastic Stem Cells / pathology
  • Plasmids / metabolism
  • Receptors, Chimeric Antigen / metabolism*
  • T-Lymphocytes / immunology*
  • Xenograft Model Antitumor Assays / methods*

Substances

  • Receptors, Chimeric Antigen

Grants and funding